Will be an interesting one to watch, I suspect this treatment (if successful in trials) will extend beyond COVID-19:
'MGC's formulation, 'ArtemiC', is a formula based on Artemisinin and Curcumin, which are well-known natural active ingredients with anti-infective properties. The Drug was designed to target viral inflammatory infections, though the effects of the drug are now being investigated on novel coronavirus 2019 (SARS-CoV-2) infected patients in a double-blind placebo-controlled, Phase II clinical trial to be held at the Israel hospital.'
The treatment may be used for other conditions and I'm sure this is being considered by MGC.
'MGC's ArtemiC is currently sold and categorized as a food supplement or nutraceutical product, requiring no new approvals or licenses.....'
A quote from Roby:
"We are anticipating the ability to produce and sell ArtemiC within a short period of time following successful completion of the Trial".
Given the quick turn around, if the treatment proves successful we can quickly move into commercialisation. Definitely less costs associated (i.e. research, production, licences, etc) with this treatment than medicinal cannabis medications in general.
Time will tell but the potential is definitely there (if trials are successful).
